These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34141776)

  • 1. Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.
    Ahmed M; Ahmed MH
    World J Clin Cases; 2021 Jun; 9(17):4133-4142. PubMed ID: 34141776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.
    Chen H; Chen Q
    Int J Biol Sci; 2022; 18(12):4756-4767. PubMed ID: 35874945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence.
    Anirvan P; Singh SP; Giammarino A; Satapathy SK
    World J Hepatol; 2021 Aug; 13(8):916-925. PubMed ID: 34552698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature.
    Nath P; Kumar R; Mallick B; Das S; Anand A; Panigrahi SC; Duseja A; Acharya SK; Chawla YK; Praharaj DL
    Cureus; 2022 Jul; 14(7):e26683. PubMed ID: 35949776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update.
    Miranda C; Garlatti E; Da Porto A; Rinaldo E; Grazioli S; Zanette G; Tonizzo M
    Arch Med Sci Atheroscler Dis; 2023; 8():e1-e10. PubMed ID: 37153375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study.
    Mahamid M; Nseir W; Khoury T; Mahamid B; Nubania A; Sub-Laban K; Schifter J; Mari A; Sbeit W; Goldin E
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1578-1581. PubMed ID: 32868652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus disease 2019 and non-alcoholic fatty liver disease.
    Bellanti F; Vendemiale G
    World J Hepatol; 2021 Sep; 13(9):969-978. PubMed ID: 34630869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids.
    Jeyakumar SM; Vajreswari A
    World J Clin Cases; 2021 Nov; 9(31):9333-9349. PubMed ID: 34877270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAFLD and COVID-19: a Pooled Analysis.
    Sachdeva S; Khandait H; Kopel J; Aloysius MM; Desai R; Goyal H
    SN Compr Clin Med; 2020; 2(12):2726-2729. PubMed ID: 33173850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time.
    Vranić L; Radovan A; Poropat G; Mikolašević I; Milić S
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.
    Iqbal U; Perumpail BJ; Akhtar D; Kim D; Ahmed A
    Medicines (Basel); 2019 Mar; 6(1):. PubMed ID: 30889791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Cordeiro A; Ribamar A; Ramalho A
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101807. PubMed ID: 34543756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
    Singh MK; Mobeen A; Chandra A; Joshi S; Ramachandran S
    Comput Biol Med; 2021 Mar; 130():104219. PubMed ID: 33486379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?
    Ahmed MH; Husain NE; Almobarak AO
    J Family Med Prim Care; 2015; 4(1):45-52. PubMed ID: 25810989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
    Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
    Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 and liver injury in individuals with obesity.
    Lempesis IG; Karlafti E; Papalexis P; Fotakopoulos G; Tarantinos K; Lekakis V; Papadakos SP; Cholongitas E; Georgakopoulou VE
    World J Gastroenterol; 2023 Feb; 29(6):908-916. PubMed ID: 36844135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.